Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ellen Ruud

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
JMIR Research Protocols|March 8, 2022
The Physical Activity and Fitness in Childhood Cancer Survivors (PACCS) Study: Protocol for an International Mixed Methods StudyHanne C Lie, Sigmund Anderssen, Corina Silvia Rueegg, et al.
British Journal of Cancer|May 15, 2018
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma StudyAna P Berbegall, Dominik Bogen, Ulrike Pötschger, et al.
Blood|April 18, 2018
Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 yearsCecilie Utke Rank, Nina Toft, Ruta Tuckuviene, et al.
Cancers|February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
The Lancet. Oncology|November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
The Lancet. Oncology|March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.
Cancers|May 23, 2020
Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian ChildrenMarion K Mateos, Morten Tulstrup, Michael Cj Quinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2020
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN StudyKeith Holmes, Ulrike Pötschger, Andrew D J Pearson, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2018
PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescentsJulianne Byrne, Desiree Grabow, Helen Campbell, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
JMIR Research Protocols|March 8, 2022
The Physical Activity and Fitness in Childhood Cancer Survivors (PACCS) Study: Protocol for an International Mixed Methods StudyHanne C Lie, Sigmund Anderssen, Corina Silvia Rueegg, et al.
British Journal of Cancer|May 15, 2018
Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma StudyAna P Berbegall, Dominik Bogen, Ulrike Pötschger, et al.
Blood|April 18, 2018
Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 yearsCecilie Utke Rank, Nina Toft, Ruta Tuckuviene, et al.
Cancers|February 5, 2020
Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)Ruth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
The Lancet. Oncology|November 17, 2018
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Dominique Valteau-Couanet, et al.
The Lancet. Oncology|March 6, 2017
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trialRuth Ladenstein, Ulrike Pötschger, Andrew D J Pearson, et al.
Cancers|May 23, 2020
Genome-Wide Association Meta-Analysis of Single-Nucleotide Polymorphisms and Symptomatic Venous Thromboembolism during Therapy for Acute Lymphoblastic Leukemia and Lymphoma in Caucasian ChildrenMarion K Mateos, Morten Tulstrup, Michael Cj Quinn, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 9, 2020
Influence of Surgical Excision on the Survival of Patients With Stage 4 High-Risk Neuroblastoma: A Report From the HR-NBL1/SIOPEN StudyKeith Holmes, Ulrike Pötschger, Andrew D J Pearson, et al.
European Journal of Cancer (Oxford, England : 1990)|October 2, 2018
PanCareLIFE: The scientific basis for a European project to improve long-term care regarding fertility, ototoxicity and health-related quality of life after cancer occurring among children and adolescentsJulianne Byrne, Desiree Grabow, Helen Campbell, et al.
Pageof 10